VABYSMO Drug Profile

Summary for Tradename: VABYSMO

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for VABYSMO

Recent Clinical Trials for VABYSMO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Junyeop Lee	PHASE4
Hospital Authority, Hong Kong	PHASE4
University of Colorado, Denver	Phase 4

See all VABYSMO clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for VABYSMO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for VABYSMO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for VABYSMO Derived from Patent Text Search

No patents found based on company disclosures

VABYSMO Market Dynamics, Financial Trajectory, Patent Estate, and Competitive Outlook

Last updated: September 8, 2026

VABYSMO, Roche’s faricimab, has become one of the fastest-growing retinal biologics since its U.S. launch in 2022. Its commercial proposition is based on dual inhibition of VEGF-A and angiopoietin-2, combined with dosing intervals that can extend to four months in eligible patients. Roche reported VABYSMO sales of approximately CHF 656 million in 2022, CHF 2.4 billion in 2023, and roughly CHF 3.4 billion in 2024. Growth has been driven by conversion from EYLEA and Lucentis, expansion in diabetic macular edema, and the October 2023 U.S. approval for macular edema following retinal vein occlusion (Roche, 2023, 2024).

The principal risks are competition from EYLEA HD, biosimilar ranibizumab and aflibercept, payer pressure, administration capacity, and the eventual development of faricimab biosimilars after the U.S. biologic exclusivity period.

What is VABYSMO and how does it compete in retinal disease?

VABYSMO is an ophthalmic bispecific antibody containing faricimab. It binds VEGF-A and angiopoietin-2, two pathways involved in retinal vascular leakage, inflammation, and neovascularization.

The FDA-approved indications are:

Indication	U.S. approval	Key commercial relevance
Neovascular age-related macular degeneration	January 2022	Large, established anti-VEGF market
Diabetic macular edema	January 2022	High treatment volume and chronic administration
Macular edema following retinal vein occlusion	October 2023	Expands addressable retinal market

VABYSMO is administered by intravitreal injection. The label permits loading doses followed by individualized dosing at intervals of one to four months, depending on disease activity and response. The ability to maintain disease control with fewer annual injections is central to its market positioning, although real-world interval performance varies by patient and physician practice (U.S. Food and Drug Administration [FDA], 2024).

How does VABYSMO compare with EYLEA and EYLEA HD?

VABYSMO competes primarily with Regeneron and Bayer’s EYLEA, aflibercept, and EYLEA HD, the higher-dose formulation approved in 2023.

Product	Active ingredient	Primary differentiation	Key competitive risk
VABYSMO	Faricimab	VEGF-A and Ang-2 inhibition; up to four-month dosing in label	EYLEA HD and payer formularies
EYLEA	Aflibercept	Long-established efficacy and broad physician familiarity	Biosimilars and EYLEA HD substitution
EYLEA HD	High-dose aflibercept	Extended dosing with the same established mechanism	Directly targets VABYSMO’s interval advantage
Lucentis	Ranibizumab	Original branded anti-VEGF franchise	Generic and biosimilar erosion
Beovu	Brolucizumab	Extended dosing potential	Safety and tolerability concerns
Susvimo	Ranibizumab implant	Port-delivery administration	Surgical implantation and device complexity

VABYSMO’s clinical and commercial advantage is not a simple reduction in injection frequency. It is the combination of a differentiated mechanism, durable dosing, and a branded product positioned before the major erosion of the anti-VEGF market. EYLEA HD limits the durability advantage, while lower-priced biosimilars pressure net price.

What is the financial trajectory of VABYSMO?

Roche’s reported sales trajectory shows rapid uptake after launch.

Year	Reported VABYSMO sales	Approximate year-over-year change	Main driver
2022	CHF 656 million	New product	U.S. launch and initial adoption
2023	CHF 2.4 billion	More than 250% growth	Conversion in AMD and DME
2024	Approximately CHF 3.4 billion	Approximately 40% growth	Broader penetration and RVO approval

Sources: Roche annual and full-year results reports.

VABYSMO moved from launch-stage revenue into Roche’s major-growth-product group within two years. The revenue curve reflects several factors:

1. Roche had an established ophthalmology commercial infrastructure through Lucentis and other products.
2. VABYSMO entered a market with substantial treatment volume and recurring injection revenue.
3. The product offered a differentiated label without requiring a new delivery device.
4. The company secured uptake in both AMD and DME rather than relying on a single indication.
5. The RVO indication increased physician familiarity and expanded the treated population.

Revenue growth is expected to decelerate as the product reaches a larger installed base and as EYLEA HD and lower-cost alternatives gain access. The key financial question is whether VABYSMO can sustain share gains while preserving net price.

What is the revenue exposure to U.S. retinal markets?

The United States is the most important VABYSMO market because of its high treatment volume, reimbursement levels, and rapid adoption of branded anti-VEGF products. U.S. revenue is exposed to:

• Medicare Part B reimbursement and buy-and-bill economics.
• Physician acquisition costs and reimbursement spreads.
• Step-edit and preferred-product policies.
• Site-of-care shifts between hospitals, physician offices, and ambulatory centers.
• Increasing use of biosimilar ranibizumab and aflibercept.
• Competing extended-duration products.

VABYSMO’s sales are also exposed to the economics of treatment burden. A drug that reduces injection frequency can create value for patients and practices, but fewer administrations can reduce procedure-related revenue for some providers. Payers may therefore evaluate total treatment cost rather than drug acquisition price alone.

When does VABYSMO lose exclusivity?

VABYSMO’s U.S. biologic exclusivity period began with FDA approval of its biologics license application on January 28, 2022. Under the Biologics Price Competition and Innovation Act, a biosimilar generally cannot be licensed until 12 years after the reference product’s first licensure, subject to statutory qualifications and patent litigation.

The earliest statutory biosimilar licensure point is therefore January 28, 2034. Commercial launch can occur later or earlier only through patent resolution, settlement, invalidity, non-infringement, or other lawful arrangements.

Exclusivity or patent event	Date or status
FDA approval of VABYSMO BLA	January 28, 2022
Twelve-year reference-product exclusivity	January 28, 2034
Small-molecule Orange Book exclusivity	Not applicable
Biosimilar pathway	Purple Book and BPCIA
Patent-driven launch date	Depends on individual patent scope and litigation outcome

The 2034 date is not the same as the end of all patent protection. Roche and Genentech can rely on composition, formulation, dosing, manufacturing, and method-of-use patents that may extend beyond or overlap with the statutory biologic exclusivity period.

What patents protect VABYSMO?

VABYSMO is protected through a layered patent estate rather than a single patent. The principal categories are:

Antibody and bispecific composition patents

These patents cover faricimab’s binding architecture, variable-region sequences, antigen binding, and dual-target activity against VEGF-A and angiopoietin-2. Composition patents are usually the most important barriers to a biosimilar because a competing product must avoid the claimed molecule while remaining clinically comparable.

Formulation patents

Formulation claims can cover concentration, buffering systems, stabilizers, surfactants, aggregation control, and storage conditions. For an intravitreal biologic, formulation protection can restrict practical biosimilar development even when the competitor uses a different manufacturing process.

Method-of-use patents

Method patents may cover treatment of AMD, DME, RVO, dosing intervals, loading regimens, retreatment criteria, and patient selection. These claims are commercially relevant because VABYSMO’s market position depends partly on extended dosing.

A biosimilar applicant may attempt to omit patented indications or dosing regimens through a so-called skinny label. That strategy can reduce, but does not eliminate, litigation exposure where the same product is promoted or prescribed for protected uses.

Manufacturing and process patents

Manufacturing claims may cover cell culture, purification, bispecific assembly, analytical testing, and product quality attributes. These patents can increase development cost and create regulatory comparability barriers, although process patents generally do not prevent all biosimilar entry by themselves.

The public patent record should be reviewed by jurisdiction and claim family. U.S. patents, international applications, continuations, terminal disclaimers, pediatric extensions, and patent-term adjustments can produce different effective dates. VABYSMO does not have the type of Orange Book patent listing associated with small-molecule drugs. Its biologic patent disclosures are evaluated through FDA Purple Book information and the BPCIA patent-exchange process.

What is the FDA and Orange Book status of VABYSMO?

VABYSMO is a biologic approved under a BLA, not a conventional drug approved under an NDA. It is therefore not subject to the standard Orange Book listing framework used for small-molecule products.

Regulatory item	Status
Product	VABYSMO
Active ingredient	Faricimab-svoa
Sponsor	Genentech, a member of the Roche Group
FDA application	BLA 761235
Approval pathway	Biologics license application
Reference product for biosimilar competition	Yes
Orange Book patent listing	Not the principal framework
Purple Book relevance	Yes

The FDA granted faricimab the “-svoa” suffix under the biological product naming convention. The product is not interchangeable with another ophthalmic biologic solely because it is biosimilar. Interchangeability requires a separate regulatory determination.

Which companies are challenging VABYSMO?

No major VABYSMO biosimilar challenger has publicly established a commercial position comparable to the biosimilar programs targeting Lucentis or EYLEA. The likely future challenger group includes large biologics manufacturers and ophthalmology-focused companies with experience in:

• Anti-VEGF antibodies.
• Intravitreal manufacturing.
• Sterile ophthalmic fill-finish.
• Medicare reimbursement.
• Biosimilar interchangeability and commercialization.

The commercial barrier is higher than for a conventional injectable because a competitor must demonstrate analytical similarity, comparable clinical performance, ophthalmic quality, sterility, container-closure integrity, and manufacturing consistency.

What generic or biosimilar entry risks exist?

VABYSMO faces limited near-term substitution risk from generics because faricimab is a biologic. The relevant risks are biosimilar competition and branded therapeutic substitution.

Near-term competitive pressure is more likely to come from:

• EYLEA HD.
• Biosimilar ranibizumab.
• Biosimilar aflibercept.
• Lower-priced branded anti-VEGF products.
• Alternative delivery systems, including implantable or sustained-release technologies.

Long-term biosimilar risk depends on the patent estate. If composition patents remain enforceable after 2034, Roche could retain protection beyond the statutory exclusivity date. If challengers invalidate or design around key patents, price competition could begin soon after biosimilar approval.

What patent litigation and settlement risks affect VABYSMO?

Publicly visible litigation risk for VABYSMO is lower than for mature anti-VEGF products because the product launched recently and no broad biosimilar wave has yet developed. The principal future litigation pathway is the BPCIA framework:

1. A biosimilar applicant files an abbreviated application.
2. The applicant provides required manufacturing and patent information.
3. The reference-product sponsor identifies patents.
4. The parties negotiate a patent-litigation package.
5. Litigation determines whether launch is blocked, delayed, or permitted.
6. Settlement may establish a negotiated entry date.

Potential settlement structures include a fixed launch date, a license covering selected patents, a covenant not to sue, or restrictions on certain indications. Settlement timing will materially affect Roche’s revenue tail.

How strong is the VABYSMO patent estate?

VABYSMO’s patent estate is commercially strong in the near and medium term because it combines a novel bispecific product with multiple possible claim layers. The strongest protection is likely to come from claims that cover the faricimab molecule or indispensable sequence elements. Formulation and dosing claims provide secondary protection but are generally more vulnerable to design-around strategies.

Protection layer	Relative strength	Main limitation
Core antibody composition	High	Validity and claim-construction challenges
Bispecific architecture	High to medium	Potential sequence or format design-arounds
Formulation	Medium	Alternative excipients and concentrations
Dosing regimen	Medium to low	Skinny-label and clinical-practice issues
Manufacturing process	Medium	Competing processes may avoid claims
Indication-specific methods	Medium	Enforcement depends on label and conduct

The estate is stronger than a single-method patent portfolio but cannot be assessed conclusively from patent counts alone. Claim scope, prosecution history, terminal disclaimers, patent-term adjustment, and litigation outcomes determine practical exclusivity.

How do VABYSMO and EYLEA HD compare commercially?

VABYSMO has an early-mover advantage in dual-pathway biology and established sales momentum. EYLEA HD has the advantage of brand familiarity, an existing aflibercept franchise, and a potentially simpler physician transition.

Factor	VABYSMO	EYLEA HD
Mechanism	VEGF-A and Ang-2	VEGF inhibition
Launch position	First major dual-target retinal biologic	Extended-duration successor to EYLEA
Dosing proposition	Up to four months for selected patients	Extended dosing depending on indication and response
Existing prescriber base	Built rapidly from 2022	Benefits from EYLEA loyalty
Biosimilar pressure	Longer-term	More immediate across aflibercept franchise
Strategic risk	EYLEA HD substitution and price pressure	VABYSMO differentiation and payer preference

The market is likely to support multiple premium retinal biologics. Product selection will depend on disease type, prior response, dosing durability, safety, payer policy, and physician economics.

What are the likely generic launch scenarios for VABYSMO?

Base case

VABYSMO continues to grow through the late 2020s, but annual growth slows as EYLEA HD captures share and branded retinal markets mature. Roche maintains premium pricing in patients for whom dual-pathway treatment or durable control is valued.

Downside case

Payers favor EYLEA HD or lower-cost biosimilars, reducing new-start volume and forcing rebates. VABYSMO remains clinically differentiated but loses net price and formulary access.

Upside case

Longer dosing intervals, strong real-world persistence, expanded retinal indications, and favorable comparative evidence support sustained share gains. Roche extends the product lifecycle through formulation, device, or next-generation delivery innovations.

A meaningful U.S. biosimilar launch is unlikely before the statutory 2034 reference-product exclusivity date unless a challenger resolves the patent estate through litigation or settlement. The more immediate threat is therapeutic competition rather than direct faricimab substitution.

What licensing deals and lifecycle strategies matter?

Roche has not relied on an external licensing transaction as the main commercial explanation for VABYSMO’s performance. The product originated from Genentech’s internal antibody and ophthalmology research platform.

Lifecycle value is more likely to come from:

• New retinal indications.
• Dosing optimization.
• Pre-filled syringe or administration improvements.
• Combination or sequencing data.
• International label expansion.
• Real-world evidence supporting four-month treatment intervals.
• Manufacturing improvements that protect supply and margins.

The most valuable lifecycle assets will be those that reduce treatment burden without creating new administration risks.

Key Takeaways

• VABYSMO generated approximately CHF 656 million in 2022, CHF 2.4 billion in 2023, and about CHF 3.4 billion in 2024.
• Faricimab’s dual VEGF-A and Ang-2 mechanism and extended dosing are the core commercial differentiators.
• EYLEA HD is the principal branded competitor; biosimilar ranibizumab and aflibercept create additional pricing pressure.
• VABYSMO is a BLA biologic and is not managed through the conventional Orange Book framework.
• The 12-year U.S. biologic exclusivity period runs to January 28, 2034.
• Direct faricimab biosimilar competition is a long-term risk, while EYLEA HD and anti-VEGF biosimilars are near-term risks.
• The patent estate likely includes composition, formulation, dosing, method-of-use, and manufacturing claims.
• Revenue durability will depend on dosing persistence, payer positioning, and Roche’s ability to defend net price.

FAQs

Is VABYSMO a biosimilar or a reference biologic?

VABYSMO is an innovator biologic and the reference product for any future faricimab biosimilar applications.

Does VABYSMO have Orange Book patents?

No conventional Orange Book listing controls VABYSMO because it was approved as a biologic under a BLA. Purple Book and BPCIA patent procedures are more relevant.

What drug is the biggest threat to VABYSMO sales?

EYLEA HD is the most direct branded threat because it offers extended dosing within the same retinal disease markets and benefits from the established EYLEA franchise.

Can a biosimilar launch immediately after January 28, 2034?

Not necessarily. January 28, 2034 is the statutory 12-year reference-product exclusivity date. Patent litigation, settlements, regulatory review, and enforceable patent claims can determine the actual launch date.

Why is VABYSMO commercially important to Roche?

VABYSMO has become a multibillion-franc growth product that offsets declines and competitive pressure in Roche’s mature pharmaceutical franchises. Its performance also strengthens Roche’s position in chronic retinal disease.

References

1. Genentech. (2022, January 28). FDA approves Genentech’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss. Roche.

2. Roche. (2023). Roche full-year results 2023. F. Hoffmann-La Roche Ltd.

3. Roche. (2024). Roche full-year results 2024. F. Hoffmann-La Roche Ltd.

4. U.S. Food and Drug Administration. (2024). Vabysmo (faricimab-svoa) prescribing information. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

6. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003.